EMA Authorised: Abraxane (paclitaxel) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

EMA authorised Abraxane (paclitaxel) by Bristol-Myers Squibb Pharma EEIG for breast cancer, pancreatic cancer, and non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Pancreatic Neoplasms;Carcinoma, Non-Small-Cell Lung. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 20/01/2026